Wallace Mark S
Department of Clinical Anesthesiology, University of California, San Diego, La Jolla, California 92037, USA.
Curr Opin Anaesthesiol. 2005 Oct;18(5):548-54. doi: 10.1097/01.aco.0000182557.09809.5e.
Neuropathic pain accounts for 25-50% of pain clinic visits with an estimated prevalence of 4 million. Neuropathic pain is often difficult to diagnose and treat with few pharmacologic options currently available. This review summarizes the latest research on the pathophysiology, diagnosis and treatment of neuropathic pain.
The diagnosis of neuropathic pain relies on an evaluation of information given by the patient and physical findings obtained by the health provider. There are several validated questionnaires that can be used. Neuropathic pain is associated with a number of different cellular and molecular mechanisms. These include abnormalities in ion channels; exaggerated responses to cytokines, enzymes and neuropeptides; and abnormal communications between large/small fibers and sympathetic/small fibers. An understanding of these mechanisms has led to mechanistic directed treatments including topical treatments, antiepileptics, antidepressants, opioids and other drugs in development that are more mechanistically driven.
Neuropathic pain is common, underdiagnosed and undertreated. Diagnosing and understanding the basic mechanisms of neuropathic pain will lead to better treatments of this difficult health care problem.
神经性疼痛占疼痛门诊就诊病例的25%-50%,估计患病率为400万。神经性疼痛通常难以诊断和治疗,目前可用的药物选择很少。本综述总结了神经性疼痛病理生理学、诊断和治疗的最新研究。
神经性疼痛的诊断依赖于对患者提供信息的评估以及医疗服务提供者获得的体格检查结果。有几种经过验证的问卷可供使用。神经性疼痛与许多不同的细胞和分子机制相关。这些机制包括离子通道异常;对细胞因子、酶和神经肽的过度反应;以及大/小纤维与交感/小纤维之间的异常通信。对这些机制的理解已导致机制导向的治疗方法,包括局部治疗、抗癫痫药、抗抑郁药、阿片类药物以及其他正在研发的更具机制驱动性的药物。
神经性疼痛很常见,诊断不足且治疗不足。诊断并理解神经性疼痛的基本机制将有助于更好地治疗这一棘手的医疗问题。